CYP2E1

What it metabolises, and why its regulation is different human data

CYP2E1 has a small active site and takes small molecules: ethanol, acetone, benzene, carbon tetrachloride, vinyl chloride, the volatile anaesthetics halothane, enflurane and isoflurane, chlorzoxazone, and paracetamol. It is also a prolific generator of reactive oxygen species during its catalytic cycle, which is why it appears in the oxidative-stress and alcoholic-liver-disease literature as a cause of injury rather than merely a route of clearance. Its regulation is the mechanistically interesting part and it is genuinely different from the other isoforms on this shelf. Transcriptional induction plays a role, but the dominant mechanism is post-translational: the presence of a substrate such as ethanol or acetone stabilises the enzyme protein against degradation, so the enzyme accumulates because it stops being destroyed rather than because more of it is made. That has a clinical consequence the transcriptional model does not predict — the induction can appear and disappear on the timescale of substrate presence, and it explains why a fasting state, which raises ketones including acetone, induces CYP2E1 without any drug being involved at all.

Sources: Lieber CS 2004 · Chien JY 1997* · Slattery JT 1996 · Flockhart DA 2021 · Guengerich FP 2008 · Leung T 2012

Inhibitors and inducers human data

The FDA potency classes are less useful here than on the other isoforms because CYP2E1 has no widely used sensitive index drug substrate and few labelled interactions; the practical classification is by mechanism and by timing instead. Ethanol is the clearest example of why timing matters: while it is present it competes for the active site and INHIBITS the metabolism of other CYP2E1 substrates, and over sustained heavy use it stabilises the enzyme and INDUCES it, so the same substance has opposite effects depending on whether it is in the blood right now. Isoniazid behaves the same way and is the better-documented pharmaceutical case. Disulfiram is a mechanism-based inactivator after its own metabolism, which makes it the reference CYP2E1 inhibitor in probe studies.

Sources: Lieber CS 2004 · Chien JY 1997* · Zand R 1993 · Slattery JT 1996 · Flockhart DA 2021

Botanical inhibitors: kava is the confirmed one contested human data

This isoform is where the in-vivo human botanical data actually land. In the 28-day probe study of four common botanical supplements, kava produced a significant inhibition of CYP2E1 — on the order of 40 percent as measured by chlorzoxazone metabolism — while leaving CYP1A2, CYP2D6 and CYP3A4/5 essentially unchanged. That is an important and slightly counter-intuitive result for anyone approaching kava from the potentiation literature, because the corpus emphasis is on CYP2C9, CYP2C19 and CYP3A4 inhibition and the confirmed in-vivo effect is on a different isoform entirely. Watercress, a rich source of phenethyl isothiocyanate, is the other botanical with a reasonable human CYP2E1 inhibition signal, and garlic constituents including diallyl sulfide inhibit CYP2E1 in animal and in-vitro work. None of these should be read as a reason to combine anything with paracetamol; the CYP2E1 story is primarily a toxicology story rather than an efficacy one.

Contested — caveat. The kava and watercress human probe findings are single controlled studies of single standardised products; the garlic and cruciferous entries are largely animal and in-vitro. A null result for one product is not a null result for every preparation of that plant, and kava products in particular differ substantially by cultivar, plant part and extraction solvent.

Sources: Gurley BJ 2005 · Van Kush Family Research Institute (Temple Pharmacopoeia Project) 2026* · Kall MA 1996 · Chien JY 1997* · Flockhart DA 2021

Clinical consequence: the paracetamol convergence human data

The reason CYP2E1 matters clinically is that it sits at the centre of the most common cause of acute liver failure in much of the world, and the mechanism is a convergence of three independent variables rather than a simple dose problem. Paracetamol is cleared mainly by glucuronidation and sulfation, with a small fraction oxidised by CYP2E1 (and CYP3A4 and CYP1A2) to the reactive quinone imine NAPQI, which is immediately conjugated by glutathione and excreted. Hepatotoxicity occurs when NAPQI production exceeds glutathione supply. Three things push that balance the wrong way at once in the classic case: CYP2E1 is induced (chronic heavy alcohol use, isoniazid therapy), glutathione is depleted (fasting, malnutrition, chronic alcohol use again), and the phase-2 conjugation capacity that normally carries most of the dose is saturated (a supratherapeutic or repeated-supratherapeutic dose). That combination — a person who drinks heavily, has not eaten for two days, and takes a few extra paracetamol for the pain — is the therapeutic-misadventure pattern, and it can cause injury at total daily doses that would be harmless in a well-nourished person who does not drink. The timing subtlety is worth holding: acute alcohol competes for the enzyme and is briefly protective, while chronic alcohol induces it and is the risk factor. The two statements are not contradictory, and confusing them is how the widely repeated and wrong claim that alcohol simply increases paracetamol toxicity acquires its confident tone.

• Phase 2 (glucuronidation and sulfation) carries most of a therapeutic paracetamol dose; CYP2E1 oxidation is a minor route until phase 2 saturates.
• Induction plus glutathione depletion plus saturated conjugation equals injury at a lower total dose than expected.
• Acute ethanol competes and is transiently protective; chronic ethanol induces and is the risk factor.
• Isoniazid inhibits while present and induces once cleared, which is why the timing of a paracetamol dose relative to it has been studied at all.
• N-acetylcysteine works by restoring the glutathione substrate supply — the antidote acts on the phase-2 side of the convergence, not on the CYP.

Sources: Slattery JT 1996 · Chien JY 1997* · Zand R 1993 · Lieber CS 2004

Polymorphism contested human data

Several CYP2E1 variants have been described, including promoter and intronic variants studied for associations with alcoholic liver disease and with occupational solvent toxicity, but none has achieved the clinically actionable status of the CYP2D6, CYP2C19 or CYP2C9 polymorphisms, and the association literature is inconsistent. The far larger sources of interindividual variation at this enzyme are physiological and behavioural: alcohol intake, nutritional state and fasting, obesity and insulin resistance, and concurrent isoniazid or solvent exposure. For practical purposes CYP2E1 activity is something you ask about rather than something you genotype.

Contested — caveat. CYP2E1 genetic association studies with liver disease and solvent toxicity are inconsistent and largely not replicated at a standard that would support clinical use. Treat the variants as research findings, not as actionable markers.

Sources: Zanger UM 2013 · Lieber CS 2004 · Leung T 2012